Sibylla Biotech is a preclinical stage company focused on developing small molecule degraders to find new therapeutics for unmet medical needs. The technology is powered by computer simulations and AI methods and is applicable to various therapeutic areas.

Sibylla Biotech

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent, Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Cigall Kadoch

Foghorn Therapeutics Inc.

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Metric
Company Name	Sibylla Biotech	Catalent, Inc.	Foghorn Therapeutics Inc.	Jazz Pharmaceuticals plc
Symbol		CTLT	FHTX	JAZZ
MSH ID	IT:SIBYLLABIOTECH	COM:CATALENT	COM:FOGHORNTX	COM:JAZZPHARMA
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Biotechnology	Drug Manufacturers - Specialty & Generic	Biotechnology	Biotechnology
Country	IT	US	US	IE
Stage
Employee Count		18K	116	2.80K
Website	sibyllabiotech.it	catalent.com	foghorntx.com	jazzpharma.com
LinkedIn			foghorn-therapeutics	jazz-pharmaceuticals
Founders

Metric
Market Cap		10.39B	265.58M	6.45B
Enterprise Value
Monthly Web Traffic	18	215.31K	2.77K
Web Traffic Growth	-0.99	0.22	-0.16
Valuation
Raised Capital			110M

Metric
Revenue	4.38B	34.16M	3.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	953M	25.49M	2.79B
EBITDA	634M	-99.25M	1.30B
Operating Income	145M	-107.91M	659.28M
Net Income	-1.04B	-98.43M	414.83M
EPS	-5.76	-2.34	6.55
Diluted EPS	-5.76	-2.34	6.10
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.22	0.93	0.85
Operating Profit Margin	-0.14	-2.70	0.17
EBITDA Margin	0.14	-2.91	0.34
Net Profit Margin	-0.23	-2.46	0.11
Return on Equity	-0.27	1.89	0.12
Return on Assets	-0.10	-0.26	0.04
Return on Capital Employed	-0.07	-0.34	0.07

IT:SIBYLLABIOTECH

Sibylla Biotech

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-11.39	-1.07	95.39
P/B Ratio	2.76	-2.02	2.21
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.61	15.72	2.03
EV Multiple	88.01	-2.58	2.48

Metric
Days Sales Outstanding	71.17		60.39
Days Payables Outstanding	41.18	123.31K	80.89
Days Inventory Outstanding	84.59		371.16
Operating Cycle	208.07		438.35
Cash Conversion Cycle	166.77	-384.60	374.47
Asset Turnover	0.45	0.13	0.34

Metric
Operating Cash Flow	268M	-118.11M	1.09B
Free Cash Flow	268M	-119.33M	1.07B
Cash Flow to Debt	0.06	-2.62	0.19
Operating Cash Flow/Sales	0.06	-3.12	0.28
Free Cash Flow Yield	-0.02	-1.04	0.11

Metric
Cash & Equivalents	289M	80.34M	1.21B
Accounts Receivable			-51.88M
Inventory	574M		597.04M
Goodwill			1.75B
Debt to Capitalization	0.58	1.54	0.61
Debt to Assets	0.49	0.15	0.52
Current Ratio	1.71	5.10	2.06
Quick Ratio	1.96	5.69	2.02

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.52	0.06
R&D to Revenue		3.49	0.21
SG&A to Revenue		1.02